Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
No OS benefit with gefitinib vs. chemo for EGFR+ NSCLC
Key clinical point: Adjuvant gefitinib provides no overall survival benefit over standard chemotherapy for EGFR-mutant, resected, stage II-IIIA non–small cell lung cancer.
Major finding: The median overall survival was 75.5 months with adjuvant gefitinib and 62.8 months with standard chemotherapy (hazard ratio, 0.92).
Study details: The phase 3 ADJUVANT trial of 222 patients.
Disclosures: The trial is sponsored by the Guangdong Association of Clinical Trials. Dr. Wu disclosed relationships with AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb/China, Lilly, MSD Oncology, Pfizer, and Roche.
Citation:
Wu Y et al. ASCO 2020, Abstract 9005.